Partner
Greg Yap
Bio + HealthcareAI
Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Epiodyne, Genesis, H1, Koala, Ophelia, Particle, Pliant (PLRX), Riva, Scribe, Vilya, and Xaira. He has also been involved in Menlo’s investments in Benchling and Recursion (RXRX).
Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure-driven platform therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million in revenue annually. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.
Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.
Supported by: Lauren Etienne, [email protected]
Investment Portfolio
Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.
Milestones
-
2012 - Founded
-
2019 - Partnered, Series C
Leadership
Saji Wickramasekara
Co-Founder & CEO
Ashu Singhal
Co-Founder & President
Partners
Cartwheel is a tech-enabled provider for youth mental health services, helping schools and families tackle the student mental health crisis.
Milestones
-
2022 - Founded
-
2023 - Partnered, Series A
Leadership
Joe English
Co-Founder & CEO
Daniel Tartakovsky
Co-Founder & COO
Partners
Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.
Milestones
-
2019 - Founded
-
2019 - Partnered, Seed
Partners
Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.
Milestones
-
2014 - Founded
-
2019 - Partnered, Series C
Partners
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Milestones
-
2019 - Founded
-
2020 - Partnered, Series A
Partners
Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.
Milestones
-
2019 - Founded
-
2021 - Partnered, Series A
Partners
Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.
Milestones
-
2013 - Founded
-
2017 - Partnered, Series B
-
2021 - IPO; NASDAQ: RXRX
Leadership
Chris Gibson
Founder & CEO
Partners
Aimmune Therapeutics
Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.
NASDAQ : AIMT
Benchling
Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.
Cartwheel
Cartwheel is a tech-enabled provider for youth mental health services, helping schools and families tackle the student mental health crisis.
Clear Labs
Clear Labs offers the only automated next-generation sequencing platform for applications including COVID diagnostics and food safety testing.
Cofactor Genomics
Cofactor Genomics is a biotech company whose mission is to enable drug development, medical research, and personalized medicine using RNA-based information and technologies.
Curie.Bio
Curie.Bio is a seed-stage venture firm and therapeutics accelerator focused on helping founders launch viable therapeutics companies.
Delfi Diagnostics
Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.
Earli
Earli’s mission is to make cancer a benign experience, by catching and curing it early.
Encoded Therapeutics
Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.
Epiodyne
Epiodyne is developing breakthrough opioid medicines to manage pain and treat opioid use disorder (OUD) with minimal potential for addiction and safety risks.
Genesis Therapeutics
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
H1
H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.
Koala Health
Koala is a modern pet healthcare provider with a mail order pharmacy offering for pet medications.
Ophelia
Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.
Particle Health
Particle Health is an API designed for healthcare innovators that gives access to vital medical data.
Pliant Therapeutics
Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
NASDAQ: PLRX
Recursion
Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.
NASDAQ: RXRX
Riva Health
Riva Health provides a digital cardiology platform designed to give patients a comprehensive, equitable, and accessible way to manage hypertension and heart disease.
Scribe Therapeutics
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying causes of genetic disorders.
Senti Biosciences
Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
NASDAQ: SNTI
Vilya
Vilya is creating a novel class of medicines to treat disease targets inside cells, leveraging its proprietary AI engine to design for drug-like properties and ultimately generate new drug candidates.
Xaira Therapeutics
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease.
q&a
Investment Approach
My goal is to be the board member I would have wanted as an entrepreneur. Ask useful questions, be the best thought partner I can be, and always try to help them with their most important problem right now.
I spent many more years as an operator and entrepreneur than as a VC, and I have empathy for the entrepreneur’s journey. Not every moment is smooth, but I’ve always learned more from difficult situations than easy ones. Meeting hard goals, turning tech into product, winning customers—it’s really hard to build a startup. I try to deliver my support, my experiences, and my networks every day.
Solving big healthcare problems takes multi-disciplinary teams, and I love investing at the intersections of AI/compute, healthcare, and life sciences. As an operator, I was fortunate to work in exciting areas of healthcare including therapeutics, digital health, genomics, and AI, and my investing is focused in those areas.
